Resarci Therapeutics LLC
Latest From Resarci Therapeutics LLC
Deal Watch: Boehringer’s Hectic Stretch Adds Up To Five Deals
Following its partnership with Dicerna, the German pharma signs a second NASH deal with MiNA and inks three cancer-related transactions, including divestitures. Also, Amgen buys out Kirin’s half of their joint venture for $780m.
Deals Shaping The Medical Industry, April 2017
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2017.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Therapeutic Areas
- Cancer
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Company Type
- Start-Up
- Parent & Subsidiaries
- Resarci Therapeutics LLC
- Senior Management
- Contact Info
-
Resarci Therapeutics LLC
c/o Purdue Foundry
1201 W. State
W. Lafayette , IN 47907
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice